TS-002404 — In the United States, 25 million people have asthma and every year more people are affected by it. Dr. Mitchell Grayson of Nationwide Children’s Hospital developed a novel use of INV-102 for the treatment and prevention of asthma. The therapeutic would alleviate symptoms of asthma or a post-viral infection like shortness of breath, chest tightness and pain, coughing and wheezing.

TS-002168 — Children have a higher chance of morbidity and mortality from respiratory viral infections. Severe respiratory viral infections like Respiratory Syncytial Virus (RSV) and Parainfluenza viruses can lead to the development of asthma in patients. Clinical researchers at Nationwide Children’s Hospital found that neuregulin-1 (Nrg-1) may be an effective and protective treatment for patients diagnosed with severe respiratory viral infections. Their successful models with mice showed that Nrg-1 may prevent post-viral airway disease and reduce mortality if further studied and applied to human patients in the future.